Business Standard

Dr Reddy's acquires Mayne Pharma's USA prescription portfolio for $105 mn

The acquisition will complement DRL's US retail prescription pharmaceutical business with limited competition products

Dr Reddy's
Premium

Sohini Das Mumbai
Dr Reddy’s Laboratories (DRL) has entered into a definitive agreement to acquire the US generic prescription product portfolio of Australia-based Mayne Pharma Group for $90 million (Rs 738 crore) upfront and contingent payments of up to $15 million (Rs 123 crore).

The acquisition will complement DRL’s US retail prescription pharmaceutical business with limited competition products. The value of the total addressable market for the pipeline and approved non-marketed products in the US is approximately $3.6 billion for the calendar year ending December 2022, according to IQVIA.

DRL’s stock was down almost 3 percent in morning trade.

DRL SA, a wholly-owned

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 27 2023 | 11:18 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com